目的 觀察地高辛片聯(lián)合益氣復(fù)脈治療慢性心力衰竭的臨床療效。方法 選取于2012年12月—2013年12月來上海市東方醫(yī)院診療的慢性心力衰竭患者64例，隨機(jī)分為對照組（29例）和治療組（35例）。對照組在一般基礎(chǔ)治療的基礎(chǔ)上口服地高辛片0.125 mg/次，1次/d。治療組在對照組基礎(chǔ)上加用注射用益氣復(fù)脈（凍干）3.9 g加入5%葡萄糖注射液或0.9%氯化鈉注射液250 mL靜脈點(diǎn)滴，1次/d。兩組均治療14 d。治療結(jié)束后對兩組患者的臨床療效、N-末端腦鈉肽前體（NT-proBNP）和心功能指標(biāo)進(jìn)行比較分析。結(jié)果 治療后，治療組和對照組的總有效率分別為97.14%、89.66%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。兩組治療后血漿NT-proBNP水平均較治療前有所降低，治療前后差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，治療組血漿NT-proBNP水平明顯低于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組心功能指標(biāo)左室舒張末期內(nèi)徑（LVEDD）、左室收縮末期內(nèi)徑（LVESD）均較治療前明顯降低，心室射血分?jǐn)?shù)（LVEF）、舒張早期/舒張晚期二尖瓣血流速度（E/A）及心輸出量（CO）均較治療前明顯升高（P<0.05、0.01）；但治療組對改善患者LVEDD、LVESD、LVEF、E/A及CO方面明顯優(yōu)于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05，0.01）。結(jié)論 在地高辛治療基礎(chǔ)上加用益氣復(fù)脈治療慢性心力衰竭可較好的改善患者的臨床癥狀和心功能狀況，對患者肝腎功能未產(chǎn)生明顯不良反應(yīng)，值得臨床推廣應(yīng)用。

Objective To evaluate the clinical efficacy of Digaoxin Tablet combined with Yiqi Fumai in the treatment of chronic heart failure. Methods Sixty-four hospitalized patients with chronic heart failure were randomly divided into treament (n = 29) and control (n = 35) groups. The Digaoxin Tablet was given to the patients in both groups, 0.125 mg/d, 14 d for a period of treatment. And Yiqi Fumai Injection was given additionally to patients in the treatment group, 3.9 g Yiqi Fumai added in 250 mL of normal saline or 5% glucose injection for iv drippiing, once daily. The treatment cycle was 14 d. After the treatment, the clinical efficacy, NT-proBNP level and cardiac function indices were analyzed. Result After treatment, the effective rates in the treat and control groups were 97.14% and 89.66%, respectively, with obvious differences (P < 0.05). Compared with those before treatment, the reduce of NT-proBNP in the treatment group was more significantly than that of the control group (P < 0.05), and the left ventricular enddistolic diameter (LVEDD), 1eft ventricular and systolic diameter (LVESD), left ventricular ejection fraction (LVEF), cardiac output (CO), and ratio of early diastolic transmitral inflow velocity to late diastolic transmitral inflow velocity (E/A) were improved obviously in both groups. However, these indices in the treatment group were better improved than those in the control group (P < 0.05, 0.01). Conclusion The Digaoxin Tablet therapy combined with traditional Chinese medicine Yiqi Fumai for the treatment of chronic heart failure can better improve the clinical symptoms, cardiac function, and quality of life of the patients with chronic heart failure with no significant impact on liver and kidney functions. Yiqi Fumai is worthy of clinical application.